{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
@if (isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif

SMART Study - Selection of coMbinAtion theRapies in Type 2 diabetes

  1. In your clinical practice how many diabetic patients you see every day?*

  2. What percentage of your diabetic patients have BMI more than >25 kg/m2 (overweight)?*

  3. What percentage of your obese diabetic patients do you prescribe SGLT2i?*

  4. What percentage of your diabetic patients are hypertensives?*

  5. What percentage of your diabetic patients have established CVD?*

  6. What percentage of your diabetic patients have CKD?*

  7. What percentage of your diabetic patients with CKD do you prescribe SGLT2i?*

  8. In your practice, the choice of add-on therapy to metformin monotherapy in patients with uncontrolled hyperglycemia AND cardiovascular or renal risk factors/prior ASCVD events is primarily decided on the basis of*

  9. If you prefer SGLT2 inhibitors as your first add-on to metformin monotherapy, is it because *

  10. In drug-naïve diabetic patient with A1c (>8.5% to 10%); what will be your approach for a powerful A1c reduction*

  11. Would you consider using an SGLT2 inhibitor in a patient with prior CVD/high risk of ASCVD events even if eGFR is ≤ 45 ml/min*

  12. Would you consider using an SGLT2 inhibitor in an uncontrolled diabetic patient with CKD for preventing further decline in renal function*

  13. In your practice, the usual line of oral treatment in drug-naïve patients with uncontrolled hyperglycaemia (A1c ≥9.0 to 10%) is to*

  14. In a progressive condition like type 2 diabetes, durability of benefit of agents used for therapy is also important. With this background, which of the following option of agents do you prefer to add to metformin as the second line*

  15. Which of the following patient profile you consider best suited for combination of Sitagliptin and Dapagliflozin?*

  16. If the patient is intolerant to Metformin, would you consider SGLT2i and DPP4i combo as the first line *

  17. Which of the following was the most common background antidiabetic therapy of your patients in whom you have initiated FDC of Dapagliflozin and Sitagliptin?*

  18. In case if you have used FDC of Dapagliflozin and Sitagliptin in patients on Insulin, did you observe or had to reduce insulin dose *

  19. In your practice what % of patients on FDC of Dapagliflozin and Sitagliptin alone, had hypoglycaemia? *

  20. Considering the cardiovascular safety of Sitagliptin (TECOS) and Dapagliflozin (DECLARE-TIMI, DAPA-HF, and DELIVER), will you consider continuing FDC of Dapagliflozin & Sitagliptin if the patient on the combination progresses to systolic Heart Failure? *

  21. In your practice what proportion of patients on FDC of Dapagliflozin and Sitagliptin had body weight loss *

  22. According to you FDC of SGLT2i + DPP4i is a suitable option for Indian T2D patients, for the following reasons (tick whichever is applicable) *

  23. In your clinical practice how many patients are on SU + Met combinations *

  24. How many patients in your clinical practice may experience hypoglycemia with SU + Met combination therapy? *

  25. How many patients in your clinical practice may experience weight gain with SU + Met combination therapy? *

  26. If patients uncontrolled on SU + Met with A1c (>8.5% to 10%) and with established CVD or with multiple cardiac risk factors, your preferred third add-on class of drug would be *

  27. Along with HbA1c reduction; which is the most important factor you consider in your diabetic patients*

  28. Which will be the best-suited patient profile; where you will be used SU + SGLT2i + Metformin FDC*

  29. In T2D patients with A1c level ≥10%; do you think the 3 drug FDC will be a better option than insulin*

  30. Please select the right patient profile for the 3 drug FDC:*
    31. # Uncontrolled T2D Uncontrolled T2D with MRF Uncontrolled T2D with eCVD Uncontrolled T2D with CKD Uncontrolled T2D with HF Obese Uncontrolled T2D
    Glimepiride + Met + Voglibose

    Glimepiride + Met + Pioglitazone

    Dapagliflozin + Sitagliptin + Metformin

    Glimepiride + Met + Dapagliflozin

    Glimepiride + Met + Sitagliptin